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Introduction
The involvement of the central nervous system in
systemic lupus erythematosus (SLE) remains a serious
but poorly understood manifestation of the disease.
Clinically, patients may present with affective dis-
orders, strokes, psychosis, or seizures. The occurrence
of psychosis, and/or seizures appears to be relatively
rare in Hong Kong Chinese SLE patients, with reported
incidences of 3% to 26%.1,2 The diagnosis of these
complications may be difficult and other processes,
which include metabolic encephalopathy, steroid-
induced psychosis, or infection must be excluded.
Various auto-antibodies have been linked to the patho-
genesis of cerebral lupus, including anti-neuronal,3-5
anti-lymphocyte,6-8 anti-ribosomal P protein,9,10 and
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anti-cardiolipin antibodies.11 The clarification of these
clinicoserological correlations would facilitate the
management of cerebral lupus and lead to a better
understanding of the disease. Anti-ribosomal P anti-
bodies show a high degree of specificity for SLE12,13
but their association with cerebral complications
have been more controversial. This topic has been
reviewed recently.14 Although most studies have
reported anti-ribosomal P antibodies to be associated
with SLE psychosis,9,10,13,15 others have questioned this
association.16-19 Furthermore, the prevalence of anti-
ribosomal P antibodies in patients with SLE psychosis
varies from 29% to 90%.9,10 Serum anti-ribosomal P
antibodies in these reports have been mainly assayed
by enzyme-linked immunosorbent assay (ELISA). The
present study aims to re-examine the association
between cerebral lupus and anti-ribosomal P anti-
bodies as detected by western blotting and ELISA.
Subjects and methods
Patients and blood samples
All patients were ethnic Chinese and were under the
care of the Department of Medicine, The University
of Hong Kong. Patients were classified as having SLE
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according to the 1982 revised criteria of the American
Rheumatism Association (ARA).20 Cerebral lupus
was defined as seizure, psychosis, or organic brain
syndrome in the absence of offending drugs or known
metabolic derangements such as uraemia, ketoacidosis,
electrolyte imbalance, or infection. Ten patients with
cerebral lupus were recruited. Of these, two were newly
diagnosed as having SLE. The other eight were known
to have SLE at presentation of their cerebral events.
Six of the eight patients were taking an oral corti-
costeroid but none had a sudden change of steroid
dose prior to the cerebral event. All patients presented
with a high fever. Eight patients had magnetic resonance
imaging changes that suggested the development of
vasculitic infarcts; cerebral lupus in the remainder was
diagnosed before magnetic resonance imaging was
available. Patients with mild personality or behavioural
changes were excluded from the cerebral lupus group.
Disease activity was measured using the SLE disease
activity index (SLEDAI),21 which combines clinical
assessments and laboratory measurements. Antibodies
against double-stranded DNA were measured using an
in-house ELISA, and complements C3 and C4 were
measured by nephelometry. Patients with an SLEDAI
≥8 were considered to have active disease; those with
an SLEDAI <4 and from 4 to 7 are categorised as
having inactive disease and moderately active disease,
respectively.
Patients in the other disease groups and control
subjects were age- and sex-matched. Rheumatoid
arthritis was defined according to the 1987 revised
criteria of the ARA.22 Other rheumatic diseases included
discoid lupus erythematosus, systemic sclerosis,
dermatomyositis, polymyositis, and primary Sjögren’s
syndrome. Lupus-related disease patients who had
fewer than four of the 11 SLE criteria were classified
as having other rheumatic diseases; antibody against
SS-A/Ro (one of the extractable nuclear antigens)
was commonly found in these patients. Serial serum
samples were also obtained from eight cerebral lupus
patients both before and after the cerebral events.
For the other patient groups and controls, only single
serum samples were analysed.
Enzyme-linked immunosorbent assay
Microtitre plates precoated with ribosomal P antigen
(1 unit per well; Immunovision, Springdale, Arkansas,
USA) were blocked with phosphate-buffered saline
(PBS) containing 1% (w/v) bovine serum albumin
(BSA) and 0.05% (v/v) Tween-20 and shaken for 1
hour at room temperature. After washing, the plates
were exposed to human sera diluted 1:50 and shaken
for 1 hour at room temperature. Plates were again
washed and exposed to alkaline phosphatase-conjugated
goat anti-human IgG (Biosource, Camavillo, California,
USA) diluted 1:1000 in PBS-Tween containing 1%
BSA and shaken for 1 hour at room temperature.
After washing, colour was developed with 1 mg/mL
p-nitrophenol phosphate disodium (Sigma, St. Louis,
Missouri, USA) in diethenolamine buffer and shaken
for 10 to 15 minutes at 37°C. The optical density at
405 nm (OD405) was related to a standard positive serum
(Light Diagnostics, Temecula, California, USA). The
OD405 reading corresponding to 1:100 dilution of this
standard was arbitrarily assigned to be 100% and the
standard curve was created by a four-fold serial dilution
from 100% to 0.39%. Test sera were considered positive
if the mean of triplicate samples was at least three
standard deviations above the mean value obtained from
40 samples of normal sera.
Western blotting
Ribosomal P antigen was obtained from Immunovision
at a concentration of 1 µg/µL. The antigen was mixed
with an equal volume of sodium dodecyl sulphate
(SDS) sample buffer (4% [w/v] SDS, 20% [v/v]
glycerol, 10% [v/v] 2-mercaptoethanol, 0.12 mol/L
Tris pH 6.8) and incubated in boiling water for 3
minutes. The mixture was applied to a 12% SDS-
polyacrylamide gel and electrophoresed at 100 volts
for 3 hours. Antigens were transferred to nitrocellulose
membrane in carbonate buffer (10 mmol/L NaHCO3,
3 nmol/L Na2CO3; pH 9.9) in 20% (v/v) methanol at
30 mA for 1.5 hours. The membrane was cut into 3-
mm–wide strips and stored at 4°C before use. Before
incubation with sample sera, the strips were blocked
with 5% non-fat milk in PBS for 1 hour at room
temperature. Sample and standard sera were diluted
1:50 in PBS with 2% BSA and 0.1% Tween-20.
The strips were immersed in sera, shaken at room
temperature for 2 hours, and washed with PBS containing
0.05% (v/v) Nonidet P40. Rabbit anti-human IgG
peroxidase conjugate (Dakopatts, Glostrup, Denmark),
diluted 1:1000, was added and the strips shaken for 1
hour at room temperature before washing. The membrane
was dried on filter paper and reacted with the enhanced
chemiluminescence western blotting detection reagents
(Amersham International Plc., Buckinghamshire, UK)
for 1 minute. After drying, the membrane was exposed
to X-ray film for about 10 seconds. The anti-ribosomal
P antibodies standard (Light Diagnostics, Temecula,
California, USA) reacted with three peptide bands
from the substrate whose molecular weights were 39 kd
(peptide P0), 20 kd (P1), and 18 kd (P2).
Statistical analysis
The Chi-squared test was used to determine the
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significance of correlation between the occurrence of
anti-ribosomal P antibodies and cerebral lupus.
Results
Incidence of cerebral lupus
During the study period (1 July 1993 to 30 June 1996),
a total of 153 patients with SLE were followed up.
Cerebral lupus was diagnosed in eight of the patients
during this time. In addition, two patients with a past
history of cerebral lupus (one in 1983 and the other in
1985) were identified by reviewing the clinical records.
This gave a prevalence of cerebral lupus with psychosis
and/or seizures of 6.5% in Chinese SLE patients.
Anti-ribosomal P antibodies were tested in all 10
patients who had cerebral lupus and in 22 lupus patients
without cerebral complications. The two groups of
patients had similar age and sex distributions.
Detection of anti-ribosomal P antibodies by
enzyme-linked immunosorbent assay
Anti-ribosomal P antibody levels measured by ELISA
were increased in 44% (14/32) of the SLE patients, none
of the 38 rheumatoid arthritis (RA) patients, 3% (1/31)
of the patients with other rheumatic diseases, and 3%
(1/40) of the control subjects (Table 1). The only patient
with a raised anti-ribosomal P antibody level in the ‘other
rheumatic diseases’ group was suffering from a lupus-
related disorder. This indicated a high specificity (99%)
but a medium sensitivity (44%) in measuring anti-
ribosomal P antibodies for the diagnosis of SLE. Of the
10 SLE patients with cerebral lupus, four (40%) had a
raised level of anti-ribosomal P antibody; this was similar
to the patients without cerebral lupus (10/22; 45%).
Measuring the anti-ribosomal P antibody level by ELISA
was thus neither sensitive (40%) nor specific (55%) for
the diagnosis of cerebral lupus.
Detection of anti-ribosomal P antibodies by
western blotting
Antibodies reacted with the P0, P1, and P2, or P1
and P2 peptides of the ribosomal P antigen in 56%
(18/32) of SLE patients, 5% (2/38) of RA patients,
16% (5/31) of patients with other rheumatic diseases,
and none of the 40 control subjects (Tables 1 and 2).
Of the five patients with other rheumatic diseases
who had anti-ribosomal P antibodies, two had a lupus-
related disorder, two had Sjögren’s syndrome, and
one had discoid lupus erythematosus. Cerebral
complications were not found in these five patients.
The sensitivity and specificity of western blotting in
detecting anti-ribosomal P antibodies to diagnose SLE
were thus comparable to the sensitivity and specificity
of ELISA (56% and 90%, respectively). A significantly
greater proportion of cerebral lupus patients had
detectable anti-ribosomal P antibodies than non-
cerebral lupus patients (90% versus 41%, respectively;
P<0.05). Hence, western blotting had a good sensitivity
(90%) but moderate specificity (59%) for the diagnosis
of cerebral lupus. Of the 18 SLE patients with anti-
ribosomal P antibodies, 13 showed reactions to all
three peptides while the remainder were reactive with
P1 and P2 peptides only. Reaction with only P1 and
P2 peptides was more common in cerebral SLE patients
(4/9) than in non-cerebral SLE patients (1/9), but the
difference was not statistically significant (Table 2).
Table 1. Detection of anti-ribosomal P antibodies by enzyme-linked immunosorbent assay or western blotting
Disease category No. of No. of patients with positive results (%)
patients
ELISA Western blotting
SLE* with cerebral complications 10  4 (40) 9 (90)
SLE without cerebral complications 22 10 (45) 9 (41)
Rheumatoid arthritis 38  0 2 (5)
Other rheumatic diseases 31 1 (3) 5 (16)
Control 40 1 (3) 0
*SLE systemic lupus erythematosus
Table 2. Detection of antibodies against the three ribosomal P peptides by western blotting
Disease category No. of No. of patients positive for: No. of
patients patients
P0, P1, and P2 P1 and P2 only negative
SLE* with cerebral complications 10 5 4 1
SLE without cerebral complications 22 8 1 13
Rheumatoid arthritis 38 1 1 36
Other rheumatic diseases 31 3 2 26
Control 40 0 0 40
*SLE systemic lupus erythematosus
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Correlation between the presence of anti-ribosomal
P antibodies and the systemic lupus erythematosus
disease activity index
Correlations between anti-ribosomal P antibodies and
the SLEDAI of the cerebral lupus and non-cerebral
lupus patients at the time of study are shown in Table
3. All cerebral lupus patients had an SLEDAI ≥8 which
by definition indicated active disease. 40% (4/10) of
the patients tested positive for anti-ribosomal P
antibodies by ELISA; and 90% (9/10) of patients tested
positive by western blotting. For eight of the cerebral
lupus patients, serial blood samples were obtained
before and after the cerebral event and when their
disease was inactive (SLEDAI <4). Anti-ribosomal P
antibodies were detectable by western blotting both
before (up to 3 months) and after (up to 3 years) the
cerebral episode. Except in one patient, anti-ribosomal
P antibodies remained detectable after the cerebral
disease had subsided. For anti-ribosomal P antibodies
measured by ELISA, serial measurements showed an
increase in antibody level during the cerebral episode
in two of the eight patients (Fig). Thus, in most patients
there was no correlation between the anti-ribosomal P
antibody level and cerebral disease.
Among non-cerebral lupus patients, there were 6, 4,
and 12 patients with active (SLEDAI >7), moderately
active (SLEDAI from 4 to 7), and inactive (SLEDAI <4)
disease, respectively, at the time of study. When measured
by ELISA, anti-ribosomal P antibodies were found to
be present in 50% (3/6), 50% (2/4), and 42% (5/12) of
patients with active, moderately active, and inactive
disease, respectively. When measured by western blotting,
anti-ribosomal P antibodies were present in 67% (2/3),
50% (2/4), and 42% (5/12) of patients with active,
moderately active, and inactive disease, respectively.
Discussion
Auto-antibodies that react with eukaryotic 60S
ribosomal phosphoproteins have been identified by
western blotting as three distinct bands—namely, P0
(38 kd), P1 (18 kd), and P2 (17 kd).23 The three proteins
share a common linear epitope within the carboxyl-
terminal 22 amino acids of each protein.24 These auto-
antibodies have been reported to occur in sera from
10% to 20% of patients with SLE.10,13,23,25,26 A higher
occurrence of these antibodies was found in the present
study (44% by ELISA and 56% by western blotting),
Table 3. Correlation between the presence of anti-ribosomal P antibodies and lupus disease activity
Cerebral lupus patients No. (%) Non-cerebral lupus patients No. (%)
Active disease Inactive disease Active disease Moderately active Inactive disease
(SLEDAI* ≥8), (SLEDAI <4), (SLEDAI ≥8), (SLEDAI, 4-7) (SLEDAI <4),
n=10 n=0 n=6 n=4 n=12
Detection method
ELISA 4 (40) 0 3 (50) 2 (50) 5 (42)
Western blotting 9 (90) 0 2 (33) 2 (50) 5 (42)
*SLEDAI systemic lupus erythematosus disease activity index
Fig. Serial measurements of anti-ribosomal P antibody level by enzyme-linked immunosorbent assay in eight patients
with cerebral lupus
The earliest sample from each patient was obtained during the acute cerebral episode
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which could be due to a genetic difference in patient
populations. A higher occurrence of anti-ribosomal P
in the Chinese population has been reported prev-
iously.15,19,27 Similarly, a higher incidence of anti-Ro
and a lower incidence of anti-Sm antibodies have also
been found in local Chinese SLE patients.1,2 Technical
differences in assay methods is a less likely explanation
because two standard methods have been used in the
current study and both showed a high prevalence of
anti-ribosomal P antibodies in our population.
A pathogenic role for anti-ribosomal P antibodies
has been suggested by studies that show an association
with cerebral disease in SLE patients,9,10,13,15 although
this has not been confirmed by other studies.16-19 The
controversy might be due to different definitions of
cerebral complications in different studies. Using the
1982 revised ARA criteria for SLE, the present study
confirms the association of psychosis and/or seizures
in SLE patients with the occurrence of anti-ribosomal
P antibodies when detected by western blotting. No
association was found if antibodies were assayed by
ELISA. This discrepancy may be explained by the
difference in the two methodologies. Although ELISA
is generally considered to have a higher analytical
sensitivity than western blotting, two different detecting
antibodies were used in this study. The two assays
were therefore not directly comparable. Another dis-
advantage of ELISA is that non-specific reactions may
be measured if the antigen used is not pure. The antigen
used in this study consistently formed several other
reaction bands with patient and normal sera in western
blotting. These bands were considered non-specific
because their positions were not those of the three
standard ribosomal P peptides. By the nature of ELISA,
these non-specific reactions were not distinguishable
and would be considered as part of the positive reaction.
Western blotting was thus more specific in defining
antibody specificities. Another problem in our study
is the relatively small number of patients with cerebral
disease and the prevalence of cerebral complications
among the SLE patients was low (6.5%). This could
be improved by performing a multicentre study.
It remains unknown whether auto-antibody pro-
duction against intracellular antigens in SLE is a cause
or an effect of the disease process. The presence of
anti-ribosomal P antibodies does not appear to be
related to the overall disease activity, as shown in our
study. In addition, this and other studies have shown
that about 50% of SLE patients without cerebral
complications have detectable anti-ribosomal P anti-
bodies. The pathogenic role of anti-ribosomal P
antibodies is thus doubtful.9,14 Small vessel infarcts
have frequently been found in the brain of patients
with cerebral lupus.28 Neuronal degeneration in these
lesions may predispose to anti-ribosomal P antibody
production, because neurons are rich in ribosomes. On
the other hand, anti-ribosomal P antibodies have not
been detected in a variety of infections and neoplasms
of the central nervous system.29 In our study, anti-
ribosomal P antibodies were detected both before and
after the cerebral events. These findings may argue
against the theory that anti-ribosomal P antibodies
might be produced as a result of neuronal damage.
If anti-ribosomal P antibodies have a pathogenic
role in cerebral lupus, the exact mechanism of specific
organ dysfunction is unknown. The antibodies inhibit
protein synthesis during in vitro protein synthesis and
when microinjected into cultured human fibroblasts.30
Several studies have failed to detect anti-ribosomal P
antibodies in cerebrospinal fluid, which suggests the
possibility of their sequestration by brain antigens.10,16
Though ribosomal P is a cytoplasmic protein, anti-
ribosomal P antibodies have been shown to react with
a plasma membrane protein located on the surface of
human neuronal cells.31,32 However, matching for a
cross-reactive brain membrane antigen using a com-
puter search has been unsuccessful.10
Regardless of the pathogenic role of anti-ribosomal
P antibodies, measuring these antibodies in the serum
from patients with SLE may be clinically useful in
the evaluation of cerebral disease. Of the numerous
tests proposed to detect cerebral lupus, none has
consistently had sufficient diagnostic sensitivity and
specificity. The diagnosis of cerebral lupus is often
based on clinical features and imaging techniques.
Our study shows that assaying anti-ribosomal P
antibodies by western blotting has a high sensitivity
and is helpful in excluding cerebral lupus if the test is
negative. A positive result, however, is not diagnostic:
41% of lupus patients tested positive, despite having
no cerebral involvement. Our results also show that
ELISA is much less useful. This may be due to the
difficulty in obtaining a purified ELISA antigen.
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